Please use this identifier to cite or link to this item: https://hdl.handle.net/1959.11/16267
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSharpley, Christopheren
dc.contributor.authorBitsika, Vickien
dc.contributor.authorWootten, Addieen
dc.contributor.authorChristie, David R Hen
dc.date.accessioned2014-12-16T09:39:00Z-
dc.date.issued2014-
dc.identifier.citationPsycho-Oncology, 23(12), p. 1350-1355en
dc.identifier.issn1057-9249en
dc.identifier.issn1099-1611en
dc.identifier.urihttps://hdl.handle.net/1959.11/16267-
dc.description.abstractObjective: The aim of this study is to explore the associations between hormone treatment variables and depression, and the nature of depression in prostate cancer (PCa) patients by comparing the severity and symptom profile of anxiety and depression in men who were currently receiving hormone therapy (HT) versus those who were not. Method: Self-reports of anxiety and depression on standardized scales of GAD and major depressive disorder (MDD) were collected from 156 PCa patients across two recruitment sites in Australia. Patients who were currently receiving HT were compared with patients not receiving HT for their severity and symptom profiles on GAD and MDD. Results: Participants receiving HT had significantly higher GAD and MDD total scores than patients who were not receiving HT. In addition, the symptom profiles of these two HT subgroups were differentiated by significantly higher scores on the key criteria for GAD and MDD plus fatigue and sleeping difficulties but not the remaining symptoms of GAD and MDD. However, there were no significant differences between HT subgroups for the degree of functional impairment experienced by these symptoms. Conclusion: Although these data confirm the association between HT and anxiety/depression, the range of GAD and MDD symptoms influenced is relatively restricted. Moreover, functional ability does not appear to be impaired by HT. These findings clarify the ways in which HT affects PCa patients and suggests that a simple total scale score for anxiety and depression may not be as helpful in designing treatment as consideration of the symptomatic profiles of PCa patients receiving HT.en
dc.languageenen
dc.publisherJohn Wiley & Sons Ltden
dc.relation.ispartofPsycho-Oncologyen
dc.titleDifferences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are noten
dc.typeJournal Articleen
dc.identifier.doi10.1002/pon.3566en
dc.subject.keywordsCentral Nervous Systemen
local.contributor.firstnameChristopheren
local.contributor.firstnameVickien
local.contributor.firstnameAddieen
local.contributor.firstnameDavid R Hen
local.subject.for2008110903 Central Nervous Systemen
local.subject.seo2008920111 Nervous System and Disordersen
local.profile.schoolSchool of Science and Technologyen
local.profile.schoolSchool of Science and Technologyen
local.profile.schoolSchool of Science and Technologyen
local.profile.emailcsharpl3@une.edu.auen
local.profile.emailvbitsik2@une.edu.auen
local.profile.emailawootten@une.edu.auen
local.profile.emaildchrist2@une.edu.auen
local.output.categoryC1en
local.record.placeauen
local.record.institutionUniversity of New Englanden
local.identifier.epublicationsrecordune-20141206-13420en
local.publisher.placeUnited Kingdomen
local.format.startpage1350en
local.format.endpage1355en
local.identifier.scopusid84915731760en
local.peerreviewedYesen
local.identifier.volume23en
local.identifier.issue12en
local.contributor.lastnameSharpleyen
local.contributor.lastnameBitsikaen
local.contributor.lastnameWoottenen
local.contributor.lastnameChristieen
dc.identifier.staffune-id:csharpl3en
dc.identifier.staffune-id:vbitsik2en
dc.identifier.staffune-id:awoottenen
dc.identifier.staffune-id:dchrist2en
local.profile.orcid0000-0001-7922-4848en
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.identifier.unepublicationidune:16504en
local.identifier.handlehttps://hdl.handle.net/1959.11/16267en
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
local.title.maintitleDifferences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are noten
local.output.categorydescriptionC1 Refereed Article in a Scholarly Journalen
local.search.authorSharpley, Christopheren
local.search.authorBitsika, Vickien
local.search.authorWootten, Addieen
local.search.authorChristie, David R Hen
local.uneassociationUnknownen
local.identifier.wosid000346002100003en
local.year.published2014en
local.subject.for2020320903 Central nervous systemen
local.subject.seo2020200409 Mental healthen
local.codeupdate.date2021-10-24T07:27:53.075en
local.codeupdate.epersoncsharpl3@une.edu.auen
local.codeupdate.finalisedtrueen
local.original.for2020320903 Central nervous systemen
local.original.seo2020undefineden
Appears in Collections:Journal Article
Files in This Item:
2 files
File Description SizeFormat 
Show simple item record

SCOPUSTM   
Citations

14
checked on Mar 23, 2024

Page view(s)

1,288
checked on Feb 11, 2024
Google Media

Google ScholarTM

Check

Altmetric


Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.